Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $32 | $45 | $60 | $84 |
| Short-Term Investments | $157 | $159 | $133 | $132 |
| Receivables | $7 | $8 | $41 | $40 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $10 | $9 | $11 |
| Total Curr. Assets | $204 | $223 | $243 | $268 |
| Property Plant & Equip (Net) | $73 | $75 | $77 | $77 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $3 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $3 | $3 |
| Total NC Assets | $76 | $78 | $80 | $80 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $281 | $301 | $323 | $349 |
| Liabilities | – | – | – | – |
| Payables | $2 | $4 | $5 | $5 |
| Short-Term Debt | $34 | $30 | $33 | $34 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $11 | $8 | $11 |
| Total Curr. Liab. | $49 | $45 | $46 | $49 |
| LT Debt | $167 | $177 | $183 | $188 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $167 | $177 | $184 | $188 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $55 | $56 | $59 | $57 |
| Total Liabilities | $216 | $222 | $229 | $237 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$405 | -$386 | -$368 | -$345 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $470 | $466 | $462 | $457 |
| Total Equity | $65 | $79 | $94 | $112 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $281 | $301 | $323 | $349 |
| Net Debt | $169 | $162 | $156 | $137 |